Which laboratory result should be closely monitored in a client receiving zidovudine?

In the context of a client receiving zidovudine, close monitoring of the complete blood count (CBC) is crucial due to zidovudine's potential side effects on hematologic parameters. Zidovudine, an antiretroviral medication used primarily in the treatment of HIV, is known to cause bone marrow suppression, which can lead to conditions such as anemia and neutropenia.

By regularly assessing the complete blood count, healthcare providers can track the client's hemoglobin levels, white blood cell count, and platelet count. Early detection of any significant changes allows for timely interventions that may prevent more serious complications associated with decreased blood cell production. Monitoring the CBC is an established practice in clients receiving zidovudine to ensure patient safety and effective management of treatment-related risks.

In contrast, while blood cultures, blood glucose levels, and blood urea nitrogen can reflect other health issues, they are not the primary laboratory results of concern specifically related to the use of zidovudine. Therefore, focusing on the complete blood count allows for the best assessment of the medication's impact on the patient's health.